8 results on '"Sattui, Sebastian"'
Search Results
2. Frailty and emergency department utilisation in adults with systemic lupus erythematosus ≤65 years of age: an administrative claims data analysis of Medicaid beneficiaries
- Author
-
Lieber, Sarah B, primary, Nahid, Musarrat, additional, Navarro-Millán, Iris, additional, Rajan, Mangala, additional, Sattui, Sebastian E, additional, and Mandl, Lisa A, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica
- Author
-
Dejaco, Christian, primary, Kerschbaumer, Andreas, additional, Aletaha, Daniel, additional, Bond, Milena, additional, Hysa, Elvis, additional, Camellino, Dario, additional, Ehlers, Lisa, additional, Abril, Andy, additional, Appenzeller, Simone, additional, Cid, Maria C, additional, Dasgupta, Bhaskar, additional, Duftner, Christina, additional, Grayson, Peter C, additional, Hellmich, Bernhard, additional, Hočevar, Alojzija, additional, Kermani, Tanaz A, additional, Matteson, Eric L, additional, Mollan, Susan P, additional, Neill, Lorna, additional, Ponte, Cristina, additional, Salvarani, Carlo, additional, Sattui, Sebastian Eduardo, additional, Schmidt, Wolfgang A, additional, Seo, Philip, additional, Smolen, Josef S, additional, Thiel, Jens, additional, Toro-Gutiérrez, Carlos Enrique, additional, Whitlock, Madeline, additional, and Buttgereit, Frank, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
- Author
-
DiIorio, Michael, primary, Kennedy, Kevin, additional, Liew, Jean W, additional, Putman, Michael S, additional, Sirotich, Emily, additional, Sattui, Sebastian E, additional, Foster, Gary, additional, Harrison, Carly, additional, Larché, Maggie J, additional, Levine, Mitchell, additional, Moni, Tarin T, additional, Thabane, Lehana, additional, Bhana, Suleman, additional, Costello, Wendy, additional, Grainger, Rebecca, additional, Machado, Pedro M, additional, Robinson, Philip C, additional, Sufka, Paul, additional, Wallace, Zachary S, additional, Yazdany, Jinoos, additional, Gore-Massy, Monique, additional, Howard, Richard A, additional, Kodhek, More A, additional, Lalonde, Nadine, additional, Tomasella, Laura-Ann, additional, Wallace, John, additional, Akpabio, Akpabio, additional, Alpízar-Rodríguez, Deshiré, additional, Beesley, Richard P, additional, Berenbaum, Francis, additional, Bulina, Inita, additional, Chock, Eugenia Yupei, additional, Conway, Richard, additional, Duarte-García, Alí, additional, Duff, Eimear, additional, Gheita, Tamer A, additional, Graef, Elizabeth R, additional, Hsieh, Evelyn, additional, El Kibbi, Lina, additional, Liew, David FL, additional, Lo, Chieh, additional, Nudel, Michal, additional, Singh, Aman Dev, additional, Singh, Jasvinder A, additional, Singh, Namrata, additional, Ugarte-Gil, Manuel F, additional, Hausmann, Jonathan S, additional, Simard, Julia F, additional, and Sparks, Jeffrey A, additional
- Published
- 2022
- Full Text
- View/download PDF
5. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
- Author
-
Sattui, Sebastian Eduardo, primary, Liew, Jean W, additional, Kennedy, Kevin, additional, Sirotich, Emily, additional, Putman, Michael, additional, Moni, Tarin T, additional, Akpabio, Akpabio, additional, Alpízar-Rodríguez, Deshiré, additional, Berenbaum, Francis, additional, Bulina, Inita, additional, Conway, Richard, additional, Singh, Aman Dev, additional, Duff, Eimear, additional, Durrant, Karen L, additional, Gheita, Tamer A, additional, Hill, Catherine L, additional, Howard, Richard A, additional, Hoyer, Bimba F, additional, Hsieh, Evelyn, additional, El Kibbi, Lina, additional, Kilian, Adam, additional, Kim, Alfred Hyoungju, additional, Liew, David F L, additional, Lo, Chieh, additional, Miller, Bruce, additional, Mingolla, Serena, additional, Nudel, Michal, additional, Palmerlee, Candace A, additional, Singh, Jasvinder A, additional, Singh, Namrata, additional, Ugarte-Gil, Manuel Francisco, additional, Wallace, John, additional, Young, Kristen J, additional, Bhana, Suleman, additional, Costello, Wendy, additional, Grainger, Rebecca, additional, Machado, Pedro M, additional, Robinson, Philip C, additional, Sufka, Paul, additional, Wallace, Zachary S, additional, Yazdany, Jinoos, additional, Harrison, Carly, additional, Larché, Maggie, additional, Levine, Mitchell, additional, Foster, Gary, additional, Thabane, Lehana, additional, Rider, Lisa G, additional, Hausmann, Jonathan S, additional, Simard, Julia F, additional, and Sparks, Jeffrey A, additional
- Published
- 2021
- Full Text
- View/download PDF
6. Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist
- Author
-
Graef, Elizabeth R, primary, Liew, Jean W, additional, Putman, Michael S, additional, Simard, Julia F, additional, Sirotich, Emily, additional, Berenbaum, Francis, additional, Duarte-García, Alí, additional, Grainger, Rebecca, additional, Harrison, Carly, additional, Konig, Maximilian F, additional, Korsten, Peter, additional, Proulx, Laurie, additional, Richards, Dawn P, additional, Robinson, Philip C, additional, Sattui, Sebastian E, additional, Ugarte-Gil, Manuel Francisco, additional, Young, Kristen J, additional, Kim, Alfred HJ, additional, and Sparks, Jeffrey A, additional
- Published
- 2020
- Full Text
- View/download PDF
7. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.
- Author
-
Dejaco C, Kerschbaumer A, Aletaha D, Bond M, Hysa E, Camellino D, Ehlers L, Abril A, Appenzeller S, Cid MC, Dasgupta B, Duftner C, Grayson PC, Hellmich B, Hočevar A, Kermani TA, Matteson EL, Mollan SP, Neill L, Ponte C, Salvarani C, Sattui SE, Schmidt WA, Seo P, Smolen JS, Thiel J, Toro-Gutiérrez CE, Whitlock M, and Buttgereit F
- Subjects
- Humans, Quality of Life, Comorbidity, Giant Cell Arteritis complications, Polymyalgia Rheumatica epidemiology
- Abstract
Objectives: To develop treat-to-target (T2T) recommendations in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR)., Methods: A systematic literature review was conducted to retrieve data on treatment targets and outcomes in GCA/PMR as well as to identify the evidence for the effectiveness of a T2T-based management approach in these diseases. Based on evidence and expert opinion, the task force (29 participants from 10 countries consisting of physicians, a healthcare professional and a patient) developed recommendations, with consensus obtained through voting. The final level of agreement was provided anonymously., Results: Five overarching principles and six-specific recommendations were formulated. Management of GCA and PMR should be based on shared decisions between patient and physician recognising the need for urgent treatment of GCA to avoid ischaemic complications, and it should aim at maximising health-related quality of life in both diseases. The treatment targets are achievement and maintenance of remission, as well as prevention of tissue ischaemia and vascular damage. Comorbidities need to be considered when assessing disease activity and selecting treatment., Conclusion: These are the first T2T recommendations for GCA and PMR. Treatment targets, as well as strategies to assess, achieve and maintain these targets have been defined. The research agenda highlights the gaps in evidence and the need for future research., Competing Interests: Competing interests: CDe has received consulting/speaker’s fees from Abbvie, Eli Lilly, Janssen, Novartis, Pfizer, Sparrow, Roche, Galapagos and Sanofi, all unrelated to this manuscript. He is an editorial board member of ARD. AK has received consultancy fees, honoraria and travel expenses from AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Gilead, Janssen, Merck Sharp and Dohme, Novartis, UCB and Pfizer, all unrelated to this manuscript. He is an editorial board member of ARD. DA received grants, speaker fees, and/or consultancy fees from Abbvie, Amgen, Galapagos, Lilly, Janssen, Merck, Novartis, Pfizer, Sandoz and Sanofi. He is an editorial board member of ARD. MB has received consulting fees from AbbVie. DC has received speaker fees from Abiogen, BMS and GSK. MCC received consultancy and/or speaker fees from GSK, Vifor, Abbvie, Astra Zeneca and Janssen and a research grant form Kiniksa Pharmaceuticals. BD has received consultancies from Novartis, Abbvie, Roche and speaker agreements from Chugai. CDu has received consultancy or speaker fees and travel expenses from Abbvie, AOP Orphan, Astra-Zeneca, Bristol-Myers-Squibb, Eli-Lilly, Janssen, Galapagos, Merck-Sharp-Dohme, Novartis, Pfizer, Roche, Sandoz, UCB, Vifor and research support by Eli-Lilly, Pfizer, UCB, all unrelated to this manuscript. BH received speaker fees and/or consultancies from Abbvie, Amgen, Astra-Zeneca, BMS, Boehringer, Chugai, GSK, InflaRx, Janssen, MSD, Pfizer, Novartis, Phadia, Roche and Vifor. ELM has received consulting fees from Boehringer-Ingelheim, Horizon Therapeutics, Alvotech Inc; speaker fees from Boehringer-Ingelheim; royalties from UpToDate. SPM has received consultancy fees (Invex Therapeutics); advisory board fees (Invex therapeutics; Gensight) and speaker fees (Heidelberg engineering; Chugai-Roche Ltd; Allergan; Santen; Teva UK; Chiesi; and Santhera). All unrelated to this manuscript. LN has received consulting fees from AbbVie. CP is or has been the principal investigator of studies by AbbVie, Sanofi and Novartis and has received consulting/speaker’s fees from Vifor, AstraZeneca, GlaxoSmithKline and Roche, all unrelated to this manuscript. CS has received consultancy fees from Abbvie, Boehringer-Ingelheim, Eli Lilly, Galapagos, Novartis, Pfizer and Roche and royalties from UpToDate. All unrelated to this manuscript. SES has received research support by Astra-Zeneca and has done provided unpaid consultancy for Sanofi. SES is supported by the Rheumatology Research Foundation RISE pilot award and Bristol Myers Squibb Foundation Robert A Winn Diversity in Clinical Trials Career Development Award, outside of the submitted work. WAS has received consultancy fees, honoraria and travel expenses from Abbvie, Amgen, Bristol-Myers Squibb, Chugai, GlaxoSmithKline, Johnson & Johnson, Medac, Novartis, Roche, and Sanofi and is principal investigator in trials sponsored by Abbvie, Amgen, GlaxoSmithKline, Novartis, Roche and Sanofi. PS has received consultancy fees from Amgen and Janssen and royalties from UpToDate, all unrelated to this manuscript. JSS received grants to his institution from Abbvie, AstraZeneca, Lilly, Novartis and Roche and provided expert advice for, or had symposia speaking engagements with, AbbVie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celltrion, Chugai, Gilead, Janssen, Lilly, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, R-Pharm, Roche, Samsung, Sanofi and UCB. He is the editor in chief of ARD. JT has received consultancy or speaker fees Bristol-Myers-Squibb, Novartis, Glaxo-Smith-Kline, Astra-Zeneca, Janssen, Abbvie, Eli-Lilly. All unrelated to this manuscript. CET-G has received consultancy fees, honoraria and travel expenses from Abbvie, BMS, Boehringer Ingelheim, Biopas, Janssen, Pfizer, Pharmalab, Roche, all unrelated to this manuscript. FB has received consultancy fees, honoraria and travel expenses from Abbvie, Novartis, Pfizer, Roche and Sanofi, all unrelated to this manuscript. He is an editorial board member of ARD. EH, LE, AA, SA, PCG, AH, TAK and MW declare no competing interests., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
8. Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group.
- Author
-
Keller KK, Mukhtyar CB, Nielsen AW, Hemmig AK, Mackie SL, Sattui SE, Hauge EM, Dua A, Helliwell T, Neill L, Blockmans D, Devauchelle-Pensec V, Hayes E, Venneboer AJ, Monti S, Ponte C, De Miguel E, Matza M, Warrington KJ, Byram K, Yaseen K, Peoples C, Putman M, Lally L, Finikiotis M, Appenzeller S, Caramori U, Toro-Gutiérrez CE, Backhouse E, Oviedo MCG, Pimentel-Quiroz VR, Keen HI, Owen CE, Daikeler T, de Thurah A, Schmidt WA, Brouwer E, and Dejaco C
- Abstract
Objective: To develop international consensus-based recommendations for early referral of individuals with suspected polymyalgia rheumatica (PMR)., Methods: A task force including 29 rheumatologists/internists, 4 general practitioners, 4 patients and a healthcare professional emerged from the international giant cell arteritis and PMR study group. The task force supplied clinical questions, subsequently transformed into Population, Intervention, Comparator, Outcome format. A systematic literature review was conducted followed by online meetings to formulate and vote on final recommendations. Levels of evidence (LOE) (1-5 scale) and agreement (LOA) (0-10 scale) were evaluated., Results: Two overarching principles and five recommendations were developed. LOE was 4-5 and LOA ranged between 8.5 and 9.7. The recommendations suggest that (1) each individual with suspected or recently diagnosed PMR should be considered for specialist evaluation, (2) before referring an individual with suspected PMR to specialist care, a thorough history and clinical examination should be performed and preferably complemented with urgent basic laboratory investigations, (3) individuals with suspected PMR with severe symptoms should be referred for specialist evaluation using rapid access strategies, (4) in individuals with suspected PMR who are referred via rapid access, the commencement of glucocorticoid therapy should be deferred until after specialist evaluation and (5) individuals diagnosed with PMR in specialist care with a good initial response to glucocorticoids and a low risk of glucocorticoid related adverse events can be managed in primary care., Conclusions: These are the first international recommendations for referral of individuals with suspected PMR, which complement the European Alliance of Associations for Rheumatology/American College of Rheumatology management guidelines for established PMR., Competing Interests: Competing interests: KKK: Research grants from Independent Research Fund Denmark, Danish Rheumatic Association and Central Denmark Region unrelated to this project. SES: Research grants from Rheumatology Research Foundation, Bristol Myers Squibb Foundation. Clinical trial support from AstraZeneca, GlaxoSmithKline; Consulting fees from Sanofi (funds toward research support); Data Safety Monitoring Board on MINT trial, Advisory Board for Sanofi (funds toward research support). E-MH: Has received grants unrelated to this manuscript from Novo Nordic Foundation, Roche, Novartis; Personal fees from AbbVie, Sanofi, SOBI, Merck Sharp & Dohme and Union Chimique Belge. AD: Consulting fees from Sanofi; Participation on a Data Safety Monitoring Board or Advisory Board for Sanofi; Board member Vasculitis Foundation. LN: Has received Honorarium from Abbvie; Trustee of the charity PMR-GCA Scotland. SM: Consulting fees from Astrazeneca; Honoraria from Vifor. KJW: Grants from Eli Lilly, Kiniksa, BMS; Consulting fees from Amgen, Sanofi. Honoraria from Amgen. CP: Consulting fee from Pfizer. MP: Consulting fee from Novartis; Clinical trial participant for Abbvie, Amgen, AstraZeneca. HIK: Honoraria from Roche, eTherapeutic Guidelines Australia; Board member Australian Rheumatology Association; Clinical trials for Roche, Abbvie, Sun, Emerald, Novartis, Biogen, Sanofi, Syneos. CEO: Consultancy for Abbvie; Speaking honoraria from Abbvie, Janssen, Novartis and Roche; Advisory board for Abbvie. WAS: Has received honoraria from Abbvie, Chugai, GlaxoSmithKline, Medac, Novartis, Roche, Sanofi ; Support for attending meetings/travel from Abbvie, Chugai, GlaxoSmithKline, Medac, Novartis, Roche, Sanofi; Participated in advisory board from Abbvie, GlaxoSmithKline, Novartis, Sanofi; Principle investigator of phases 2 and 3 studies sponsored by Abbvie, GlaxoSmithKlinie, Novartis and Sanofi. EBrouwer: As an employee of the UMCG received a speaker fee for a talk on GCA at a post EULAR symposium in the Netherlands in 2023 which was paid to the UMCG; As an employee of the UMCG received grants from the Dutch Arthritis Society DAS and the EU/EFPIA/Innovative Medicines Initiative 2 Joint Undertaking Immune-Image grant no 831514 which were paid to the UMCG. SM: Consultancy on behalf of her institution for Roche/Chugai, Sanofi, AbbVie, AstraZeneca, Pfizer; Investigator on clinical trials for Sanofi, GSK, Sparrow; speaking/lecturing on behalf of her institution for Roche/Chugai, Vifor, Pfizer, UCB, Novartis and AbbVie; chief investigator on STERLING-PMR trial, funded by NIHR; patron of the charity PMRGCAuk. No personal remuneration was received for any of the above activities. Support from Roche/Chugai to attend EULAR2019 in person and from Pfizer to attend ACR Convergence 2021 virtually. SM is supported in part by the NIHR Leeds Biomedical Research Centre. VD-P has received honorarium from Abbvie, Chugai, Novartis, BMS, Support for attending meetings/travel from Novartis; Participated in advisory borad from Abbvie, Novartis. All other authors have no competing interests., (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ on behalf of EULAR.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.